Ranbaxy settles with Takeda on Actos suit
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories has settled outstanding patent litigation with Takeda Pharmaceutical Company, allowing it to launch a generic version of Takeda's antidiabetic, Actos (pioglitazone hydrochloride), in the US.